OncoAlert

Dear Colleagues, Presenting another great @GuardConsortium Educational Capsule. This month we have our friend @Ecastromarcos of Hospital 12 de Octubre in Madrid🇪🇸talking about the Changes in the Management of Metastatic Hormone Sensitive #ProstateCancer cc: @cdanicas @dralvaropinto @drenriquegrande @nachoduranm @DrJaVallejo @abraocantoMD @docjavip @AlvarezMa89031 @DrFelixGuerrero @BerUrologia @AnaPlatabello1 @scocmem @OncBrothers @Helena_de_Palma @F_lopez_campos @mjuanfi81 @EurUrolOncol Pinging OncoAlert Faculty @montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas @brian_rini @AOmlin #OncoAlertAF @nataliagandur @realbowtiedoc @Onco_Cifu88 @scocmem @AmandaNizamMD

Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial buff.ly/rlNOUAB In this phase III trial, investigators evaluated whether adding nivolumab, with or without ipilimumab, to concurrent chemoradiotherapy could improve outcomes for unresectable stage III #NSCLC #LungCancer 🫁 compared with standard durvalumab consolidation. After 30.5 months of follow-up, neither experimental strategy significantly📈 improved progression-free or overall survival versus durvalumab. Both nivolumab-containing regimens were associated with higher rates of pneumonitis, highlighting ongoing unmet needs and the importance of developing more effective and safer treatment approaches. @peters_solange @danieltanmd @RamalingamMD @Tony_Calles Pinging Faculty @ChristianRolfo @GlopesMd @NarjustFlorezMD @StephenVLiu @bmassutis @s_couraud @marinagarassino @UmbertoMalapel1 @g_mountzios @CharuAggarwalMD @christine_lovly @jillfeldman4 @bensolomon1 @VanitaNoronha @DrSanjayPopat @alexdrilon @JordiRemon @DrJNaidoo @caliraf @MartinReck2 @Latinamd @JulienMazieres @TerriConneran #OncoAlertAF @nataliagandur @acampsmalea @BRicciutiMD @HHorinouchi @FernandoOnco @ElisaAgostinett @to_be_elizabeth @realbowtiedoc @Erman_Akkus @MarioBalsaMD @DrMirallas @GIMedOnc @UOzkerim @DrRishabhOnco @Onco_Cifu88 @PaulJiL @DaisukeKotani @DraMartinezLago @p_ciracimd @AmandaNizamMD @scocmem @DrVilmaPBarcia

#ESTRO26 is officially open! Opening session chaired by @Mat_Guc reminding us why radiation oncology does not just adapt to the future - we build it together 💪🏼💪🏼 And this year in #Stockholm… we ROCK 🎸 #radonc #medphys #rtt #OncoAlert @OncoAlert @ESTRO_RT

🧬Universal germline genetic testing is recommended for all patients with pancreatic cancer, yet a new #OpenAccess study from @UGrewalMD and colleagues suggests many still face barriers to testing access and uptake. Read the study: acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… @OncoAlert @PanCAN

Chemotherapy-induced anemia as a prognostic factor for overall survival in patients with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy and cystectomy link.springer.com/article/10.100… In this retrospective study of 175 patients with muscle-invasive #BladderCancer treated with cisplatin 🧪 based neoadjuvant chemotherapy followed by radical cystectomy, preoperative anemia was highly prevalent, affecting 95% of patients. Moderate-to-severe anemia (grade >1) was independently associated with significantly worse overall, relapse-free, and specific survival outcomes, whereas red blood cell 🩸 transfusions showed no prognostic impact. Additional adverse prognostic factors included elevated neutrophil count and nodal involvement after surgery. These findings highlight preoperative anemia as a potential therapeutic target warranting further investigation. #BladderCancer @PignotG

IDH1 Mutations Are Associated with Favorable Outcom es in ProstateCancer europeanurology.com/action/showPdf… Prostate cancers harboring IDH1 or IDH2 mutations🧬 represent a distinct molecular subtype with unique clinical and genomic features. Although these tumors often present with high stage and grade disease, patients experience significantly improved📈overall, metastasis-free, and hormonal therapy progression-free survival compared with matched controls. IDH1-mutant tumors show enrichment for FOXA1 and CTNNB1 alterations, absence of common #ProstateCancer drivers, and evidence of metabolic, epigenetic, and transcriptional reprogramming, supporting a biologically unique and clinically favorable subgroup. @DrPhilKantoff @neerajaiims @nikolausschultz @VanAllenLab @EAntonarakis @LotanLab @rovingatatuscap @laurasenamd @ziremozay @OncoAlert 🚨 @Silke_Gillessen @AOmlin @weoncologists

🎥 In this #ESTRO26 opening interview, Matthias Guckenberger, President of ESTRO, sets the tone for the days ahead in Stockholm. What does “Innovating Radiation Oncology, Together” really mean in practice? Find out in the video. #radonc @oncoalert @vjoncology @Mat_Guc

Wrapping up the reirradiation session after I did my presentation-which had the least evidence of any disease site-start reporting more outcomes UGI and HPB brachy teams! A great session and lots to think about @ESTRO_RT #ESTRO26 #thisisbrachytherapy

✨ Starting #ESTRO26 with over 700 participants joining today’s pre-meeting courses and our newly launched Clinical Bootcamp! An exciting start to the congress week ahead in Stockholm!

📢 Expanding our reach for ESTRO 2026! 🌟 We are thrilled to welcome @OncoAlert and @VJOncology as our official Media Partners for #ESTRO26! 🙏 Whether you are joining us in person or following from afar, get ready for unparalleled coverage of the latest in #radonc.

🌟 Meet our #IJGC #EditorialFellow! Kamilla L. Dávid, MD (@kamillaldavid) 🇭🇺 is a third-year OBGYN resident currently pursuing a research fellowship in gynecologic oncology at Houston Methodist Hospital, USA. From Budapest to Houston, her work focuses on translating evidence into better patient recovery and surgical quality 👩‍⚕️📊 @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @RParejaGineOnco @lchiv4 @annafagottimd @HousseinELHAJJ3 @AinhoaMada @ElePanizzolo @esragbilir @ChiaraAinio @alicezampolini @Chiara_4997 @Lawalqdus @Dra_AnaConde #IJGConline #Research #Prevention #Treatment #Diagnostic #GynCancer #WomenHealth #SoMe #SoMe4GynOnc

OncoAlert is beyond proud to partner with our friends at ESTRO as we look ahead to what promises to be an incredible #ESTRO26 in Stockholm 🇸🇪 Together with ESTRO, the ESTRO Ambassadors and our friends and collaborators at VJ Oncology, we are committed to bringing the latest advances in Radiation Oncology directly from the podium in Stockholm to your mobile device — in real time! We Are ALL OncoAlert 🚨 For Colleagues...By Colleagues #RadOnc @ESTRO_RT @yasemin09896924 @LindaMrissa @christian_roenn @Valeriadionisi @gerryhanna @clchiang_hk @mtugceyilmaz @B_Tomasik @gmpetrianni @CiroFranzese1 @Atem84 @piet_ost @brachyexpert @BlanceS90 @The_PT_Explorer @BarbaraJereczek @Mat_Guc @ZilliThomas @AnnaKirby17 @PBlanchardMD @achoud72 Pinging OA faculty @MKnoll_MD @_ShankarSiva @Icro_Meattini @seanmmcbride @NiuSanford @nataliagandur @acampsmalea @to_be_elizabeth

VOLGA is positive: perioperative durvalumab + neoadjuvant EV improves EFS and OS in cisplatin-ineligible MIBC. Key difference from KEYNOTE trials: no adjuvant ADC here, only IO. So in pCR patients, is adjuvant ADC really needed? Looking forward for details. @OncoAlert @ONCOassist @Uromigos @tompowles1 @Larvol @MedwatchKate

Plan ahead! Did you know you can add #JCO Central events to your @ASCO 2026 agenda? Search for “JCO” in the online #ASCO26 meeting program: meetings.asco.org/meetings/2026-… @OncoAlert @JCO_ASCO @UniGenova @ConquerCancerFd @ASCOPost

This is what we're all here for - courtesy of ChatGPT (other AI are available) & our very own Manchester guide to #ESTRO26 @RT_physics @MCRCnews @ESTRO_RT @OncoAlert ⬇️

I came to #ESTRO26 yesterday, but here's the @RT_physics @MCRCnews Manchester posse flying today @ClinOncologist says some escaped the photo! Stockholm here we come! @syeepei @Al_McWilliam @elivaos @marianneaznar 🥳

Ready for the afternoon session starting with breast reirradiation-an area where there is quite a bit of evidence. @ESTRO_RT #ESTRO26 #thisisbrachytherapy

🔬 Adjuvant therapy in RCC: from data to daily practice Join this expert-led webinar to stay up to date with the latest congress insights and how they translate into clinical decision-making. 💡 What to expect: • Key highlights from major congresses • Practical interpretation of adjuvant data in RCC 👨‍⚕️ Expert speaker: Philippe Barthélémy 📅 Date & time: 22 June 2026 17:00 CEST 👉 Join live or catch up on-demand: us02web.zoom.us/webinar/regist… @OncoAlert

@achoud72 @ESTRO_RT @RT_physics @MCRCnews So looking forward to seeing our amazing friend @achoud72 !!!

@OncoAlert @ESTRO_RT #Manchester will be there! @RT_physics @MCRCnews #ESTRO26

👋Hej! Stockholm is ready for #ESTRO26! We are excited to welcome participants from around the world for another inspiring edition! ✨